2018 was a banner year not just for novel drug approvals but for novel device approvals as well. Last year, 59 novel drugs and 106 novel devices were greenlighted by the regulatory agency compared to 46 novel drugs and 99 novel devices approved in 2017. Now, let's take a look at the biotech stocks that await a ruling from the FDA in February 2019.
from RTT - Biotech http://bit.ly/2B7nJHW
via IFTTT
No comments:
Post a Comment